Previous 10 | Next 10 |
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with this event. For further details see: Esperion Therapeutics (ESPR) Presents At 39th Annual Healthcare Conference - Slideshow
On Wednesday morning, Biotech company Esperion Therapeutics (NASDAQ: ESPR) released unaudited preliminary results for the fourth quarter of its fiscal year 2020. However, investors don't seem too impressed with these results and they are selling off shares of the drugmaker as a resu...
Esperion (ESPR) announces it has entered into a definitive agreement with Serometrix to in-license its oral, small molecule PCSK9 inhibitor program, and says it expects Q4 2020 U.S. net product revenue to be between $8M and $8.5M.The small molecule PCSK9 inhibitor program is intended for...
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent sequential growth for NEXLETOL ® (bempedoic acid) tablets and NEXLIZET ® (bempedoic acid and ezetim...
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 a.m. Eastern Time. ...
Swiss authorities have approved Daiichi Sankyo Europe and Esperion Therapeutics' ([[ESPR]] -3.0%) Nilemdo (bempedoic acid) tablet and Nustendi (bempedoic acid and ezetimibe) tablet, for high low-density lipoprotein cholesterol.Bempedoic acid and its fixed combination drug product with ez...
- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and its fixed combination drug product with ezetimibe both deliver ...
Esperion Therapeutics (ESPR) has appointed Sheldon Koenig as COO, effective today. Tim M. Mayleben, President and CEO said, “Sheldon is the right leader at the right time to navigate our company through the opportunities that lie ahead of us as we continue a period of rapid g...
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating officer, effective today. Koenig will report directly to Tim M. Mayleben, president and chief execu...
Esperion ([[ESPR]] +3.6%) announces pooled data from four of Phase 3 studies evaluating Nexletol (bempedoic acid) as an adjunct to diet for lowering LDL-C ("bad" cholesterol) in adults.Data analysis from a subgroup of 580+ patients who cannot tolerate any dose of a statin, show...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...